The missing linkage: what pharmacogenetic associations are left to find in CYP3A?

Bibliography

• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22(1):1-21
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez CP, Jover R, Donato MT, Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007;8(2):185-94
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360(9340):1155-62
   PubMed Web of Science ®Google Scholar
• Stevens JC, Hines RN, Gu C, Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307(2):573-82
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Brian WR, Sari MA, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38(2):207-13
   PubMed Web of Science ®Google Scholar
• Haehner BD, Gorski JC, Vandenbranden M, Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996;50(1):52-9
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-91
   PubMed Web of Science ®Google Scholar
• Brenner C, Duggan D. Oncogenomics: molecular approaches to cancer. Hoboken: Wiley-Liss; 2004
   Google Scholar
• Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68(4):978-89
   PubMed Web of Science ®Google Scholar
• Carlson CS, Eberle MA, Rieder MJ, Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74(1):106-20
   PubMed Web of Science ®Google Scholar
• de Bakker PI, Yelensky R, Pe'er I, Efficiency and power in genetic association studies. Nat Genet 2005;37(11):1217-23
   PubMed Web of Science ®Google Scholar
• Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006;7(10):781-91
   PubMed Web of Science ®Google Scholar
• Montana G. Statistical methods in genetics. Brief Bioinform 2006;7(3):297-308
   PubMed Web of Science ®Google Scholar
• Li A. The hepatocyte review. In: Berry MN, Edwards AM, editors, Dordrecht; Boston: Kluwer Academic Publishers; 2000. p. 391-410
   Google Scholar
• Hashimoto H, Toide K, Kitamura R, Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218(2):585-95
   PubMedGoogle Scholar
• Thompson EE, Kuttab-Boulos H, Yang L, Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006;6(2):105-14
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Malmebo S, Johansson A, Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003;31(6):755-61
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23
   PubMed Web of Science ®Google Scholar
• Westlind A, Lofberg L, Tindberg N, Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999;259(1):201-5
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62(1):162-72
   PubMed Web of Science ®Google Scholar
• Schellens JH, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988;37(13):2507-10
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24(5):475-90
   PubMedGoogle Scholar
• Ozdemir V, Kalowa W, Tang BK, Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10(5):373-88
   PubMedGoogle Scholar
• Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006;79(4):350-61
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Vega JM, Rogers JD, Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000;40(11):1274-9
   PubMed Web of Science ®Google Scholar
• Klein TE, Chang JT, Cho MK, Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics research network and knowledge base. Pharmacogenomics J 2001;1(3):167-70
   PubMedGoogle Scholar
• Committee HCPAN. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee 2001. Available at: http://www.cypalleles.ki.se/ [Last accessed June 2009]
   Google Scholar
• Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10(3):187-216
   PubMedGoogle Scholar
• Kinirons MT, O'Shea D, Kim RB, Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999;66(3):224-31
   PubMed Web of Science ®Google Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999;48(5):716-27
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Thummel KE, Watkins PB. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv 2005;5(3):151-3
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Jaffe JM, Walker AH, Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90(16):1225-9
   PubMed Web of Science ®Google Scholar
• Ando Y, Tateishi T, Sekido Y, Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999;91(18):1587-90
   PubMed Web of Science ®Google Scholar
• Lepper ER, Baker SD, Permenter M, Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11(20):7398-404
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Hustert E, Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004;60(4):231-6
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 2006;34(7):1198-207
   PubMed Web of Science ®Google Scholar
• Floyd MD, Gervasini G, Masica AL, Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003;13(10):595-606
   PubMedGoogle Scholar
• Ball SE, Scatina J, Kao J, Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66(3):288-94
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Pizarro RM, CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002;71(3):196-204
   PubMed Web of Science ®Google Scholar
• Kadlubar FF, Berkowitz GS, Delongchamp RR, The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12(4):327-31
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Troxel AB, Norman S, Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 2007;166(12):1392-9
   PubMed Web of Science ®Google Scholar
• Spurdle AB, Goodwin B, Hodgson E, The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002;12(5):355-66
   PubMedGoogle Scholar
• Zeigler-Johnson C, Friebel T, Walker AH, CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004;64(22):8461-7
   PubMed Web of Science ®Google Scholar
• Bangsi D, Zhou J, Sun Y, Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 2006;24(1):21-7
   PubMed Web of Science ®Google Scholar
• Paris PL, Kupelian PA, Hall JM, Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8(10):901-5
   PubMed Web of Science ®Google Scholar
• Kittles RA, Chen W, Panguluri RK, CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002;110(6):553-60
   PubMed Web of Science ®Google Scholar
• Powell IJ, Zhou J, Sun Y, CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 2004;172(5 Pt 1):1848-52
   PubMed Web of Science ®Google Scholar
• Kang YS, Park SY, Yim CH, The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009;85(3):312-8
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11(9):773-9
   PubMedGoogle Scholar
• Wong M, Balleine RL, Collins M, CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75(6):529-38
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 2008;64(10):1033-5
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Isoherranen N, Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007 ;82(4):410-26
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54(10):1271-94
   PubMed Web of Science ®Google Scholar
• Chu W, Fyles A, Sellers EM, Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007;28(10):2139-42
   PubMed Web of Science ®Google Scholar
• Shimada N, Iwasaki M, Kasuga Y, Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009;54(4):209-15
   PubMed Web of Science ®Google Scholar
• Zhenhua L, Tsuchiya N, Narita S, CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett 2005;225(2):237-43
   PubMed Web of Science ®Google Scholar
• Tucker AN, Tkaczuk KA, Lewis LM, Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 2005;217(1):61-72
   PubMed Web of Science ®Google Scholar
• Vaarala MH, Mattila H, Ohtonen P, The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer 2008;122(11):2511-6
   PubMed Web of Science ®Google Scholar
• Op den Buijsch RA, Christiaans MH, Stolk LM, Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007;21(4):427-35
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82(6):711-25
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee YJ, Jang SB, Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007;64(2):185-91
   PubMed Web of Science ®Google Scholar
• Jun KR, Lee W, Jang MS, Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009;87(8):1225-31
   PubMed Web of Science ®Google Scholar
• Press RR, Ploeger BA, den Hartigh J, Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009;31(2):187-97
   PubMed Web of Science ®Google Scholar
• Fukudo M, Yano I, Yoshimura A, Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008;18(5):413-23
   PubMed Web of Science ®Google Scholar
• Quteineh L, Verstuyft C, Furlan V, Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008;103(6):546-52
   PubMed Web of Science ®Google Scholar
• Crettol S, Venetz JP, Fontana M, CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30(6):689-99
   PubMed Web of Science ®Google Scholar
• Wang J. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diagn 2009;9(4):383-90
   PubMed Web of Science ®Google Scholar
• Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45(1):13-31
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Xu N, Azziz R. Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(7):2909-12
   PubMed Web of Science ®Google Scholar
• Smit P, van Schaik RH, van der Werf M, A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 2005;90(9):5313-6
   PubMed Web of Science ®Google Scholar
• Bacsi K, Kosa JP, Borgulya G, CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int 2007;80(3):154-9
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Rennert H, Walker AH, Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer 2008;123(6):1385-9
   PubMed Web of Science ®Google Scholar
• Kreutz R, Bolbrinker J, van der Sman-de Beer F, CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J 2008;8(6):416-22
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26(8):1895-900
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 2006;80(2):179-91
   PubMed Web of Science ®Google Scholar
• Schirmer M, Rosenberger A, Klein K, Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007;8(5):443-53
   PubMed Web of Science ®Google Scholar
• Perera MA, Thirumaran RK, Cox NJ, Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J 2009;9(1):49-60
   PubMed Web of Science ®Google Scholar
• Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988;28(11):1040-5
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Bertino JS Jr, Rocci ML Jr, Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998;64(3):269-77
   PubMed Web of Science ®Google Scholar
• Schmidt R, Baumann F, Hanschmann H, Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 2001;26(3):193-200
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48(11):1350-5
   PubMed Web of Science ®Google Scholar
• Hosohata K, Masuda S, Yonezawa A, MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res 2009;26(7):1590-5
   PubMed Web of Science ®Google Scholar
• Pavek P, Pospechova K, Svecova L, Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol 2009 published online 25 August 2009, doi:10.1016/j.bcp.2009.08.017
   Google Scholar
• Khan AA, Chow EC, van Loenen-Weemaes AM, Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur J Pharm Sci 2009;37(2):115-25
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Watanabe H, Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004;23(1):100
   PubMedGoogle Scholar
• Bertilsson G, Heidrich J, Svensson K, Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95(21):12208-13
   PubMed Web of Science ®Google Scholar
• Blumberg B, Evans RM. Orphan nuclear receptors–new ligands and new possibilities. Genes Dev 1998;12(20):3149-55
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Moore JT, Wade L, An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92(1):73-82
   PubMed Web of Science ®Google Scholar
• Xie W, Barwick JL, Simon CM, Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14(23):3014-23
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P, Thummel KE, Fisher JM, Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997;51(5):741-54
   PubMed Web of Science ®Google Scholar
• Thummel KE, Brimer C, Yasuda K, Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001;60(6):1399-406
   PubMed Web of Science ®Google Scholar
• Tirona RG, Lee W, Leake BF, The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9(2):220-4
   PubMed Web of Science ®Google Scholar
• Hustert E, Zibat A, Presecan-Siedel E, Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001;29(11):1454-9
   PubMed Web of Science ®Google Scholar
• Lin YS, Yasuda K, Assem M, The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos 2009;37(6):1295-304
   PubMed Web of Science ®Google Scholar
• Lamba J, Lamba V, Strom S, Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008;36(1):169-81 published online 20 May 2009, doi:10.1016/j.leukres.2009.04.027
   PubMed Web of Science ®Google Scholar
• Matsumura K, Saito T, Takahashi Y, Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 2004;65(2):326-34
   PubMed Web of Science ®Google Scholar
• Plant N. The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 2007;1770(3):478-88
   PubMed Web of Science ®Google Scholar
• Kosuge K, Chuang AI, Uematsu S, Discovery of osmosensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5). Mol Pharmacol 2007;72(4):826-37
   PubMed Web of Science ®Google Scholar
• Gandara DR, Kawaguchi T, Crowley J, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27(21):3540-6
   Google Scholar
• Bertrand J, Treluyer JM, Panhard X, Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 2009;65(7):667-78
   PubMed Web of Science ®Google Scholar
• Ekhart C, Doodeman VD, Rodenhuis S, Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009;67(1):50-60
   PubMed Web of Science ®Google Scholar
• Veiga MI, Asimus S, Ferreira PE, Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2009;65(4):355-63
   PubMed Web of Science ®Google Scholar
• Singh R, Srivastava A, Kapoor R, Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009;380(2):169-77
   PubMed Web of Science ®Google Scholar
• Hartman A, van Schaik RH, van der Heiden IP, Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res 2009, published online 20 May 2009, doi:10.1016/j.leukres.2009.04.027
   Google Scholar
• Provenzani A, Notarbartolo M, Labbozzetta M, The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009;14(1):23-31
   PubMed Web of Science ®Google Scholar
• Tsai SM, Lin CY, Wu SH, Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009;404(2):160-5
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhai D, He H, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol 2009;65(6):579-84
   PubMed Web of Science ®Google Scholar
• Geisler T, Schaeffeler E, Dippon J, CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9(9):1251-9
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Morange PE, Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101(8):1088-93
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008;64(6):589-97
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB, Gama CS, Lobato MI, Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics 2008;18(7):599-609
   PubMed Web of Science ®Google Scholar
• Tirelli S, Ferraresso M, Ghio L, The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Med Sci Monit 2008;14(5):CR251-4
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van Agteren M, CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008;18(4):339-48
   PubMed Web of Science ®Google Scholar
• Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008;29(1):1-5
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Cusatis GA, Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85(2):155-63
   PubMed Web of Science ®Google Scholar
• Miao J, Jin Y, Marunde RL, Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009;9(5):319-26
   Google Scholar
• Rodriguez-Antona C, Axelson M, Otter C, A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J Biol Chem 2005;280(31):28324-31
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008;73(11):1052-9
   PubMed Web of Science ®Google Scholar